NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Neuphoria Therapeutics Inc. (NEUP) Stock Analysis

Neuphoria Therapeutics Inc. (NEUP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NEUP

$3.77

+$0.01 (+0.27%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NEUP with… →

NEUP Key Statistics

As of Sep 4, 2026
Trading
Open
$3.74
Previous Close
$3.76
Day's Range
3.73–3.78
52-Week Range
3.19–21.40
Volume
21.90K
Valuation
Market Cap
$20.38M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.90
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$15.49M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.40M
1-Year Return
−68.37%
Dividend and dates
Avg Volume
196.83K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NEUP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.84%
2025+13.12%
2024−80.69%
2023−68.17%
2022−62.95%
2021 (partial year)−14.80%

As of September 4, 2026.

NEUP Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2024$0.00−$15.49M—
2023$0.00−$21.38M—
2022$181.36K−$14.97M−8253.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$0.00—−$17.80M−$15.49M—
2023$0.00—−$21.56M−$21.38M—
2022$181.36K—−$14.68M−$14.97M−8253.6%

Annual figures as reported, in the company's reporting currency. As of June 30, 2024.

NEUP Valuation vs Biotechnology Median

Median of 656 stocks
MetricNEUPBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Neuphoria Therapeutics Inc. (NEUP) carries a market capitalisation of $20.38M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 7.

The most recent close on file for NEUP is $3.77, dated September 4, 2026. That is +$0.01 (+0.27%) against the previous close. The 52-week range on file runs from $3.19 to $21.40. The latest close sits 18.18% above that 52-week low.

Financial Health

Fiscal 2024 revenue came to $0.00. The same year closed with a net loss of $15.49M. Profit margin runs at 0%. Trailing earnings per share are −7.9.

Across the 3 fiscal years on file, revenue moves from $181.36K in 2022 to $0.00 in 2024. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Daily returns over the trailing 4 years annualize to a volatility of 196.58%. The trailing one-year price return is −68.37%. Measured over 3 years, that is −45.77% a year compounded.

Growth & Income

No dividend is on file for NEUP.

Across the complete calendar years on file, 2025 returned +13.12% and 2024 returned −80.69%. Of the 4 complete calendar years on file, 1 finished higher. So far in 2026 the price is −2.84%.

Peer Comparison

Neuphoria Therapeutics Inc. (NEUP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Neuphoria Therapeutics Inc. NEUP $20.38M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Neuphoria Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.

Visit website →